Aduro Biotech CDMRP Grant for Prostate Cancer Vaccine Development
9/6/2012 10:21:32 AM
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces the award of a Congressionally Directed Medical Research Programs (CDMRP) grant from the Department of Defense. The grant of $867,846 will be used to complete the preclinical development of a novel therapeutic cancer vaccine for prostate cancer.
comments powered by